US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Sonoma Pharmaceuticals, Inc. - Common Stock (NQ:SNOA)

1.240 -0.010 (-0.80%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonoma Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
From Sonoma Pharmaceuticals, Inc.
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
From Sonoma Pharmaceuticals, Inc.
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
From Sonoma Pharmaceuticals, Inc.
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Via ACCESS Newswire
News headline image
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Via ACCESS Newswire
News headline image
National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
Via ACCESS Newswire
News headline image
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Via ACCESSWIRE
News headline image
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
Via ACCESSWIRE
< Previous 1 2 3 Next >